The Effects of Different Doses of Intravenous Esketamine on Postoperative Sleep and Chronic Pain in Patients Undergoing Thoracoscopic Lung Resection Surgery: A Randomized Controlled Trial
This randomized controlled trial demonstrates that low-dose intravenous esketamine infusion significantly improves postoperative sleep quality in patients undergoing thoracoscopic lung resection but does not prevent chronic pain at 3 or 6 months post-surgery.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
After a major surgery, the body's recovery is often hindered not just by the physical wound, but by a quiet, invisible struggle: the inability to sleep. For patients undergoing thoracoscopic lung resection, a minimally invasive procedure to remove part of a diseased lung, the night following the operation can be particularly restless. This lack of rest is more than a minor inconvenience; poor sleep in the days after surgery is a known risk factor for confusion and delirium, and it can slow the healing process. While doctors have long used a combination of painkillers and nerve blocks to manage the sharp pain of the incision, the question of how to restore a patient's natural sleep cycle has remained less clear. Researchers have been investigating whether a specific drug, esketamine, which is a variant of the anesthetic ketamine, could help. This drug is known for its ability to calm the brain and reduce pain, but its effects on sleep and long-term comfort after lung surgery were not fully understood.
A team of researchers at Wenzhou Medical University in China set out to find the answer by conducting a carefully controlled experiment. They recruited ninety patients scheduled for elective lung surgery and divided them into three equal groups. The goal was to see if the amount of esketamine given during the operation mattered. One group received a high dose of the drug, another received a low dose, and the third group received a harmless saltwater solution as a control. All patients were given standard anesthesia to keep them asleep during the surgery, and the only difference was the addition of esketamine or saltwater. The patients, the surgeons, and the nurses monitoring them did not know which group anyone belonged to, ensuring that the results would be based purely on the drug's effects and not on expectations.
The researchers checked on the patients the day after surgery and again three days later, asking them to rate their sleep quality using a standard questionnaire. They also followed up with the patients three and six months later to ask about any lingering pain at the surgical site. The results revealed a distinct pattern. On the first day after surgery, the group that received the low dose of esketamine had a significantly lower rate of sleep disturbance compared to the group that received only saltwater. By the third day, this advantage was even clearer: the patients who received the low dose reported better sleep scores than those in the control group. However, the group that received the high dose of esketamine did not show the same improvement; their sleep quality was similar to the control group. This suggests that there is a "sweet spot" for this medication, where a smaller amount helps the brain settle into rest, but a larger amount might actually interfere with that process.
Despite the improvements in sleep, the study found that esketamine did not change the long-term pain experience for these patients. When the researchers contacted the patients three and six months after their operations, there was no difference in the amount of chronic pain reported between the groups who received esketamine and the group who received saltwater. The drug also did not significantly reduce the amount of other painkillers the patients needed in the immediate days following surgery. The study did note that the drug was safe to use; while some patients experienced mild side effects like dizziness or nausea, these occurred at similar rates across all three groups, and no serious adverse events were linked to the different doses.
The findings offer a nuanced view of how this medication works. The researchers suggest that at a low dose, esketamine may gently calm the brain's stress response and reduce inflammation, allowing the body to return to a natural sleep rhythm. However, at higher doses, the drug might overstimulate certain parts of the brain, effectively canceling out the benefits and keeping the patient awake or agitated. While the study did not solve the problem of chronic pain after lung surgery, it provides a clear, evidence-based strategy for improving the immediate postoperative experience. For patients facing this type of surgery, a carefully calibrated low dose of esketamine administered during the operation could mean the difference between a restless, difficult recovery and a night of restorative sleep.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.